ALKS FY2025 SEC EDGAR DEF 14A #102 of 168 in industry

Alkermes plc. CEO pay ratio

The CEO earned $8.0M in FY2025 against median worker pay of $266,757 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
L2
Filing date
2026-04-06
Industry
Chemicals & Pharmaceuticals
Industry rank
#102/168

Data updated August 2026

Subscribe to Alkermes plc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
30:1
Below Average (Scale: 0–1000:1)
CEO pay
$8.0M
Median worker
$266,757

Answer first

Alkermes plc.'s FY2025 CEO total of $8.0M ranks #684 of 1,423 complete filings; its 30:1 pay ratio ranks #1136. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $266,757. Industry placement uses the FY2025 SIC-28 peer cohort (# 102 of 168, 40th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#684
$8.0M of 1,423 FY2025
Ratio rank
#1136
30:1 of 1,423
Industry pct
40th
below the industry median pay ratio

How Alkermes plc. ranks nationally

Alkermes plc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,002,710 Top 48% higher than 52% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Alkermes plc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($8.0M) against pay ratio (30:1) for Alkermes plc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3149280.95861815.4857435011286884.513999419.128.4:131.9:135.5:139.1:142.6:1CEO total payPay ratio (CEO : median worker)Alkermes plc., CEO total pay: 8002710 · Pay ratio (CEO : median worker): 30:1Alkermes plc.Protagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, IncJanux Therapeutics, Inc., CEO total pay: 13506231 · Pay ratio (CEO : median worker): 30:1Janux Therapeutics, Inc.Green Plains Inc., CEO total pay: 3642469 · Pay ratio (CEO : median worker): 31:1Green Plains Inc.Iovance Biotherapeutics, Inc., CEO total pay: 4755679 · Pay ratio (CEO : median worker): 31:1Iovance Biotherapeutics, Inc.Structure Therapeutics Inc., CEO total pay: 8520403 · Pay ratio (CEO : median worker): 29:1Structure Therapeutics Inc.
Alkermes plc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Alkermes plc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Alkermes plc.

Complete DEF 14A pay-ratio filings for this CIK across FY2023–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
30:1
FY2025
vs prior FY
-15:1
from FY2024 45:1
CEO $ YoY
-21%
$8.0M latest
Filings shown
3
FY2023–2025
Alkermes plc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2023 $9.4M - $218,453 43:1 -
2024 $10.2M +8.2% $225,915 45:1 +2:1
2025 $8.0M -21% $266,757 30:1 -15:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1520262, FY2023–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
30:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.0M
Companies in Industry
168
vs. Industry Median
Below
#102 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Alkermes plc.: MODEST · HEAVY pay ratio

Alkermes plc.'s 30:1 ratio ranks #1136 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 30× the median employee ($266,757) in FY2025.

Median employee $266,757 (ELITE-MED); MODEST · HEAVY stamps put about 30 median-wage years per CEO year.

CEO Total Pay

$8.0M

FY2025 Summary Compensation, near median

Pay Ratio

30:1

Below typical

Alkermes plc. in the lower-ratio third

Alkermes plc.'s 30:1 ratio ranks #1136 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Alkermes plc.'s $8.0M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #684 and ratio rank #1136 split - treat 30:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$8.0M
Median Employee Pay
$266,757
Pay Ratio
30:1
Filing Date
2026-04-06

Company Info

Ticker
ALKS
CIK
1520262
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
L2
View SEC filings →
SEC EDGAR DEF 14A for CIK 1520262, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Alkermes plc.'s 30:1 ratio ranks #1136 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Alkermes plc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Corsair Gaming, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $3K lighter vs Alkermes plc.); STEEP · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Sirius Xm Holdings Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $10K heavier vs Alkermes plc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
LivaNova PLC · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $23K heavier vs Alkermes plc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
JBT MAREL Corp · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $26K lighter vs Alkermes plc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Protagonist Therapeutics, Inc (SIC 28 pole)

Protagonist Therapeutics, Inc stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Alkermes plc.'s MODEST filing.
National dual ranks · #684/#1136

Alkermes plc.'s FY2025 package sits #684 by CEO dollars and #1136 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Alkermes plc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Alkermes plc. (CIK 1520262), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.